What Pulsetto Actually Is
Pulsetto is a consumer-grade transcutaneous vagus nerve stimulation (tVNS) device worn on the neck. It delivers low-level electrical pulses through skin-contact electrodes positioned over the cervical vagus nerve bilaterally. The device connects to a smartphone app that lets users select pre-set programmes (labelled for stress, sleep, pain, and similar categories) and adjust intensity. Sessions typically run 4-15 minutes.
Unlike implanted VNS systems (which require surgery and deliver current directly to the vagus trunk via a cuff electrode), Pulsetto is non-invasive. It sits in the same product category as other consumer neck-worn devices (e.g., Xen by Neuvana targets the auricular branch via earbuds; gammaCore targets the cervical vagus but is FDA-cleared for specific indications). The key question for any consumer device is whether the electrical signal actually reaches the vagus nerve through skin, subcutaneous tissue, and muscle in sufficient strength to produce a meaningful physiological effect.
The Stimulation Parameters
Vagus nerve stimulation research typically uses specific, well-characterised parameters: frequency (commonly 20-30 Hz for taVNS, 25 Hz in many clinical trials), pulse width (200-300 microseconds), and current intensity (0.5-5 mA for transcutaneous devices). Implanted VNS devices like those from LivaNova use similar frequencies but can deliver current directly to the nerve at lower intensities because there is no tissue barrier.
Pulsetto’s published specifications describe adjustable intensity and pre-programmed stimulation patterns. However, the device’s exact frequency, pulse width, and waveform characteristics are not fully disclosed in peer-reviewed literature in the same way that clinical-grade devices document their parameters. This lack of transparency makes it difficult to compare Pulsetto directly to the stimulation protocols used in published vagus nerve stimulation research.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Clinician-applied tVNS
- Implanted VNS and neuromodulation
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
What the Evidence Shows for Cervical Transcutaneous VNS
The best-studied non-invasive cervical VNS device is gammaCore (electroCore), which has received FDA clearance for cluster headache (2017), migraine (both acute and preventive), and has been studied in clinical trials including PRESTO (acute migraine with aura) and PREMIUM (preventive migraine). gammaCore’s clearance rests on randomised controlled trial data submitted to a regulatory body.
For auricular transcutaneous VNS (taVNS), which targets the auricular branch of the vagus in the ear, there is a growing body of research. A common target is the cymba conchae, where ABVN fibre density is highest. Studies using 25 Hz stimulation at this site have shown fMRI activation of the nucleus tractus solitarius (NTS) and connected brainstem regions — the same areas activated by implanted VNS.
For consumer-grade cervical devices like Pulsetto specifically, the peer-reviewed evidence base is considerably thinner. The company cites internal studies and user surveys, but large, independent, randomised controlled trials published in high-impact journals are not yet available. This does not mean the device cannot work — it means the evidence is not yet strong enough to make confident clinical claims.
Potential Benefits and Limitations
What Might Work
Transcutaneous electrical stimulation of the neck can activate afferent nerve fibres, including vagal afferents. If the stimulation parameters are appropriate and the current penetrates sufficiently, users might experience increased parasympathetic tone (reflected in higher heart-rate variability), a sense of relaxation, and reduced perceived stress. Some users report improved sleep onset and reduced anxiety. These reports are consistent with what vagal activation would be expected to produce, though a placebo contribution cannot be excluded without controlled trials.
What to Be Cautious About
Claims that any consumer device can treat clinical depression, epilepsy, inflammatory bowel disease, or autoimmune conditions are not supported by the evidence for non-prescription devices. These conditions have been studied with implanted VNS (which delivers current directly to the nerve trunk) or FDA-cleared devices under medical supervision. Generalising those results to a consumer device with different parameters and delivery method is not scientifically valid.
The skin and subcutaneous tissue between a neck electrode and the cervical vagus nerve creates significant impedance. Whether enough current reaches the vagus nerve — and specifically the right fibre populations — at consumer device intensities remains an open question in the neuromodulation literature.
How Pulsetto Compares to Other Approaches
gammaCore (electroCore): FDA-cleared cervical nVNS for headache disorders. Prescription device with published RCT data. Stimulation parameters are well-characterised and publicly documented. Higher price point, requires prescription in most markets.
NEMOS/tVNS (auricular): CE-marked auricular tVNS device with clinical trial support for epilepsy and depression in Europe. Targets the ear (cymba conchae) rather than the neck. Published fMRI validation of NTS activation.
Resonance-frequency breathing: Free, no device needed. Breathing at approximately 0.1 Hz (roughly 6 breaths per minute) maximises respiratory sinus arrhythmia and vagal afferent input. Meta-analyses show consistent HRV improvements. The main limitation is that it requires practice and sustained attention.
Cold face immersion (dive reflex): Free, evidence-based vagal activation. Submerging the face in cold water (10-15 degrees C) for 15-30 seconds reliably triggers trigeminal-vagal bradycardia. Acute effect, not a sustained intervention.
Should You Buy One?
Pulsetto is unlikely to cause harm at typical consumer intensities, and some users report subjective benefits. If you find it helps with relaxation or sleep and you can afford it, it may be a reasonable addition to a broader vagal-health routine that includes breathing practices, exercise, and adequate sleep.
However, it should not be purchased as a substitute for medical treatment of any diagnosed condition. If you have epilepsy, treatment-resistant depression, gastroparesis, or an inflammatory disorder, these require evaluation and management by appropriate specialists. The evidence base for consumer-grade VNS devices does not currently support their use as primary treatments for these conditions.
Before purchasing, consider whether your goals might be equally well served by free, evidence-supported approaches: resonance-frequency breathing (6 breaths per minute), regular aerobic exercise (which consistently improves vagal tone across meta-analyses), or HRV biofeedback with a validated wearable. These approaches have stronger published evidence and cost nothing beyond the initial investment in learning them. See our guide to HRV biofeedback and vagal tone training for practical protocols.
For an evidence-based guide to vagus nerve anatomy, function, and stimulation methods — both natural and device-based — explore the My Vagus Nerve & Me book. Get the eBook here and make informed decisions about your vagal health.
